AAPG - Ascentage Pharma Group International

AAPG - Ascentage Pharma Group International

https://www.ascentage.cn

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Ascentage Pharma Group International - Unsponsored ADR ( AAPG ) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Commentary • 1 week, 6 days ago • score: 0.28

Ascentage Pharma Group International - Unsponsored ADR (AAPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here's Why Ascentage Pharma Group International - Unsponsored ADR ( AAPG ) Is a Great 'Buy the Bottom' Stock Now

Zacks Commentary • 2 weeks ago • score: 0.40

After losing some value lately, a hammer chart pattern has been formed for Ascentage Pharma Group International - Unsponsored ADR (AAPG), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock ...

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday - Amber International ( NASDAQ:AMBR ) , Ascentage Pharma Group ( NASDAQ:AAPG )

Benzinga • 2 weeks, 6 days ago

U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Monday. Shares of Keurig Dr Pepper Inc. KDP fell sharply during Monday's session after the company announced the acquisition of JDE Peet's. Keurig Dr Pepper shares dipped 7.8% to $32.38 on Monday.

Ascentage Pharma to Participate in Evercore China Biotech Summit

GlobeNewswire • 1 month, 2 weeks ago • score: 0.09

ROCKVILLE, Md. and SUZHOU, China, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma Group International ( NASDAQ: AAPG. HKEX: 6855 ) ( "Ascentage Pharma" or the "Company" ) , a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that the ...

Ascentage Pharma to Participate in Evercore China Biotech Summit - Ascentage Pharma Group ( NASDAQ:AAPG )

Benzinga • 1 month, 2 weeks ago • score: 0.08

ROCKVILLE, Md. and SUZHOU, China, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma Group International AAPG HKEX: 6855 ) ) ( "Ascentage Pharma" or the "Company" ) , a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that the Company's ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.

52W High

$48.45

52W Low

$16.50

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.00

Valuation

As of 2023-12-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

13.44

P/S (TTM) (<3 favorable)

7.03

P/B (<3 favorable)

60.58

Ownership

Source: Overview

Insiders (1–5% typical)

0.00%

Institutions (25–75% balanced)

0.00%

Shares Outstanding

348,267,000

Float

174,846,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2023-12-31 (Overview)

Revenue (TTM)

903,029,000

Gross Profit (TTM)

875,581,000

EPS (TTM)

-0.17

Profit Margin (>10% good)

-0.40%

Operating Margin (TTM) (higher better)

0.23%

ROE (TTM) (>15% strong)

-0.52%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

4.77

Momentum

Bearish momentum

Value

-0.5960

Previous

-0.6152

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025